세계의 네뷸라이저 시장 : 시장 인사이트, 경쟁 구도 시장 예측(2032년)

Nebulizers Market by Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer), Portability (Tabletop Nebulizer and Portable Nebulizer), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Emergency Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising burden of chronic respiratory diseases, the surge in cigarette smoking, increase in home healthcare devices, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.

The nebulizers market was valued at USD 1,374.60 million in 2024, growing at a CAGR of 7.32% during the forecast period from 2025 to 2032, to reach USD 2,412.36 million by 2032. The nebulizer market is experiencing significant growth due to the rising burden of chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and the surge in smoking which has led to an increased demand for effective treatment options, including nebulizers, which are essential for delivering medication directly to the lungs. Simultaneously, the increase in home healthcare devices has made nebulizers more accessible and convenient for patients who prefer or require home-based treatment, driving market expansion. Additionally, growing awareness and comprehensive screening programs have also played a crucial role by enhancing early diagnosis and management of respiratory conditions, thereby increasing the need for nebulization therapy. Furthermore, the surge in product launches and regulatory approvals by leading market players introduces advanced and innovative nebulizer technologies, such as portable and more efficient devices, which cater to diverse patient needs and preferences. Collectively, these factors contribute to robust market growth by addressing the needs of a growing patient population, advancing technology, and improving accessibility and management of respiratory diseases during the forecast period from 2025 to 2032.

Nebulizers Market Dynamics:

According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions.

Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately, 1 in 20 people globally suffered from chronic respiratory diseases.

Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people have COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases.

As the incidence of respiratory disorders rises, driven largely by smoking and environmental factors, there is a heightened need for nebulizers, which are critical in delivering medication directly to the lungs for effective symptom relief and disease management.

Additionally, as per the recent data provided by GLOBOCAN, in 2022, globally the estimated new cases of trachea, bronchus, and lung cancer was 2.48 million, and the projections are expected to rise by 4.25 million by the year 2045. For patients with lung cancer, nebulizers can be used to deliver medications that help manage side effects such as shortness of breath, cough, and mucus production. As the incidence of lung cancer rises, the need for supportive care tools, including nebulizers, increases. Additionally, lung cancer patients often undergo treatments that can lead to respiratory complications, further driving the demand for nebulization therapy to alleviate symptoms and improve quality of life.

Additionally, companies are amplifying their production of nebulizers and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in May 2024, Medline announced the addition of the Hudson RCI TurboMist small volume nebulizer to its respiratory care portfolio. The TurboMist delivered medication treatments in as little as three minutes and was designed to be the fastest small volume nebulizer available.

Thus, the factors mentioned above are likely to boost the market of nebulizers during the forecasted period.

However, the availability of alternative drug delivery and drug loss during medication dosage to be consumed may hinder the future market of nebulizers.

Nebulizers Market Segment Analysis:

Nebulizers by Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer), Portability (Tabletop Nebulizer and Portable Nebulizer), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Emergency Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment of the nebulizers market the jet nebulizers are expected to hold a significant share in 2024. The large market share of this product segment can be attributed to the growing patient adoption of these devices, quick treatment, mobility, and simplicity. Moreover, jet nebulizers are capable of delivering the drug in the form of droplets in the size range of 1-5 mm, with the help of baffles incorporated due to their design. These nebulizers are mostly used for bronchodilator administration to produce a physiological response. Both technical and patient factors are involved in the growth performance of the jet nebulizers segment. Technical factors, like the gas flow, the volume of the nebulizer solution, and the nebulizer output, play a crucial role in better drug delivery. Also, the low cost of jet nebulizers is significantly boosting the nebulizers market growth. This, in turn, is expected that the jet nebulizer segment will grow over the forecast period, which will also help in driving the overall global nebulizers market growth.

Furthermore, due to precise medication administration to the lungs and lower residual quantities, jet nebulizers are gaining commercial acceptability, which improves market penetration. All these advantages of these devices make physicians more inclined to use jet nebulizers.

In addition, new product approvals are also likely to upsurge the Global Nebulizers market during the forecasted period. For instance, in January 2021, Wellinks announced the initiation of IRB approved study of digital health solutions for COPD, it will utilize a Bluetooth(TM) enabled version of Wellinks' Flyp Nebulizer and a suite of connected diagnostic tools including spirometry and pulse-oximetry.

Additionally, a shift in trend from table-top to portable devices will offer assistance in remote settings. This will increase the acceptance of nebulizers for patients. Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global nebulizers market during the forecast period.

North America is expected to dominate the overall nebulizers market:

North America is expected to account for the highest proportion of the nebulizers market in 2024, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, increase in technological advancement, increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of nebulizers during the forecast period.

According to the recent data and stats provided by the American Lung Association (2024), in 2022, among children, asthma was more common in males accounting for 7.0% of the population in the United States and 5.4% in females. Additionally, as per the same source, asthma among adults is 10.8% for females and 6.5% for females across the region of the United States. Asthma, a chronic respiratory condition characterized by airway inflammation and constriction, requires consistent management to control symptoms and prevent exacerbations. Nebulizers are vital in delivering medications, such as bronchodilators and corticosteroids, directly to the lungs, providing quick and effective relief from asthma symptoms. As the prevalence of asthma rises globally, driven by factors like environmental pollution and increased awareness of the condition, there is a corresponding increase in the need for nebulizers thereby boosting the overall market across the region.

Additionally, as per the data provided by the Centre for Disease Control and Prevention (2024), in 2022, 4.6% of adults had been diagnosed with COPD, emphysema, or chronic bronchitis in the United States. As nebulizers are essential for delivering medication to help alleviate symptoms and manage these diseases, the prevalence of such conditions directly drives demand for these devices. With a notable portion of the adult population needing ongoing respiratory care, healthcare providers and patients are likely to seek out nebulizers to improve quality of life and manage symptoms more effectively thereby boosting the market.

Furthermore, as per the recent data and stats provided by the Centre for Disease Control and Prevention (2023), approximately 11.5% of U.S. adults aged 18 and older smoked cigarettes, totaling around 28.3 million smokers. At that time, over 16 million Americans were living with a smoking-related disease. The high prevalence of smoking-related diseases drives the need for nebulizers, as they are essential in delivering medication to alleviate symptoms and improve respiratory function. This significant patient population creates a strong demand for nebulizers, boosting the market.

Further, in North America and at the global level the United States represents the largest market worldwide supported by developed healthcare infrastructure and strong adoption of technologically advanced products owing to the rise in healthcare expenditure by the government and increased prevalence and incidence of respiratory disease as mentioned above. One such technological advancement is the AeroEclipse BAN nebulizer, it is the world's only breath-actuated small volume nebulizer, developed by Trudell Medical International in Canada.

The increasing number of product development activities in the region is further going to accelerate the growth of the nebulizers market. In August 2021, Smiths Medical announced the launch of the acapella(R) choice blue vibratory PEP therapy system. Vibratory PEP therapy is a drug-free supplemental treatment that can reduce COPD flare-ups and hospital length of stay by 1.5 days. The acapella(R) Choice blue system is designed to effectively deliver medication when combined with a nebulizer.

Therefore, the above-mentioned factors are expected to bolster the growth of the nebulizers market in North America during the forecast period.

Nebulizers Market Key Players:

Some of the key market players operating in the Nebulizers market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., Allied Healthcare Products Inc., TEKCELEO, BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Convexity Scientific Inc., Rossmax International Ltd., and others.

Recent Developmental Activities in the Nebulizers Market:

• In May 2024, Medline announced the latest addition to its respiratory care portfolio, the Hudson RCI TurboMist small volume nebulizer is designed to be the fastest small volume nebulizer on the market, TurboMist delivered medication treatments in as little as three minutes.
• In September 2021, Resyca, Recipharm collaborated with Medspray and boarded its first pharmaceutical customer on its soft mist inhaler (SMI) platform. The SMI platform includes a portable disposable nebulizer with a microspray nozzle created by spray expert Medspray, to produce a near-monodisperse aerosol with a high lung dosage.
• In March 2021, PARI Pharma GmbH announced the authorization of its LAMIRA Nebulizer System for delivering Insmed's ARIKAYCE (amikacin liposome inhalation suspension) in Japan. This followed the approval of ARIKAYCE by Japan's Ministry of Health, Labour and Welfare (MHLW) on the same date. The LAMIRA was the first drug-specific eFlow Technology nebulizer registered outside Europe and North America.

Key takeaways from the nebulizers market report study:

• Market size analysis for current nebulizers size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the nebulizers market.
• Various opportunities available for the other competitors in the nebulizers market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current nebulizers market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for nebulizers market growth in the coming future?

Target audience who can benefit from this nebulizers market report study:

• Nebulizers product providers
• Research organizations and consulting companies
• Nebulizers-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in Nebulizers
• Various end-users who want to know more about the nebulizers market and the latest technological developments in the nebulizers market.

Frequently Asked Questions for the Nebulizers Market:

1. What are nebulizers?

• Nebulizers are medical devices that convert liquids into aerosols which are then easily transported to the lower respiratory tract. These are commonly used as bronchodilators and help in the treatment of patients suffering from respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory diseases.

2. What is the market for nebulizers?

• The nebulizers market was valued at USD 1,374.60 million in 2024, growing at a CAGR of 7.32% during the forecast period from 2025 to 2032, to reach USD 2,412.36 million by 2032.

3. What are the drivers for the nebulizer market?

• The nebulizer market is experiencing significant growth due to the rising burden of chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and the surge in smoking which has led to an increased demand for effective treatment options, including nebulizers, which are essential for delivering medication directly to the lungs. Simultaneously, the increase in home healthcare devices has made nebulizers more accessible and convenient for patients who prefer or require home-based treatment, driving market expansion. Additionally, growing awareness and comprehensive screening programs have also played a crucial role by enhancing early diagnosis and management of respiratory conditions, thereby increasing the need for nebulization therapy. Furthermore, the surge in product launches and regulatory approvals by leading market players introduces advanced and innovative nebulizer technologies, such as portable and more efficient devices, which cater to diverse patient needs and preferences. Collectively, these factors contribute to robust market growth by addressing the needs of a growing patient population, advancing technology, and improving accessibility and management of respiratory diseases during the forecast period from 2025 to 2032.

4. Who are the key players operating in the nebulizer market?

• Some of the key market players operating in the nebulizers market include Koninklijke Philips N.V., Omron Healthcare, Inc., Aerogen, PARI GmbH, GF Health Products, Inc., Allied Healthcare Products Inc., TEKCELEO, BMC Medical Co., Ltd., Medtronic PLC, Invacare Corporation, Trudell Medical International, Nouvag AG, Timesco Healthcare Ltd., LAICA S.p.A., Vega Technologies Inc., Besco Medical Limited, DeVilbiss Healthcare LLC, Feellife Health Inc., Convexity Scientific Inc., Rossmax International Ltd., and others.

5. Which region has the highest share in the nebulizers market?

• North America is expected to account for the highest proportion of the nebulizers market in 2024, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, increase in technological advancement, increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in mergers, acquisitions, product launches, and other market activities across the region are expected to escalate the market of Nebulizers during the forecast period.

Table of Contents

1. Nebulizers Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Nebulizers Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Nebulizers Market Key Factors Analysis

• 5.1. Nebulizers Market Drivers
  • 5.1.1. The rising burden of chronic respiratory diseases
  • 5.1.2. The surge in cigarette smoking
  • 5.1.3. Increase in home healthcare devices
  • 5.1.4. Increasing awareness and screening programs
  • 5.1.5. Increase in product launches and approvals by key market players across the globe.
• 5.2. Nebulizers Market Restraints and Challenges
  • 5.2.1. The availability of alternative drug delivery
  • 5.2.2. Drug loss during medication dosage to be consumed
• 5.3. Nebulizers Market Opportunities
  • 5.3.1. The increase in a shift towards home-based healthcare solutions

6. Nebulizers Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Nebulizers Market Assessment

• 7.1. By Type
  • 7.1.1. Jet Nebulizer
  • 7.1.2. Ultrasonic Nebulizer
  • 7.1.3. Mesh Nebulizer
• 7.2. By Portability
  • 7.2.1. Tabletop Nebulizer
  • 7.2.2. Portable Nebulizer
  • 7.2.3. Others
• 7.3. By End-User
  • 7.3.1. Hospitals and Clinics
  • 7.3.2. Ambulatory Surgical Centers
  • 7.3.3. Emergency Centers
  • 7.3.4. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Nebulizers Market Size in USD million (2022-2032)
    • 7.4.1.2. Canada Nebulizers Market Size in USD million (2022-2032)
    • 7.4.1.3. Mexico Nebulizers Market Size in USD million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Nebulizers Market Size in USD million (2022-2032)
    • 7.4.2.2. Germany Nebulizers Market Size in USD million (2022-2032)
    • 7.4.2.3. United Kingdom Nebulizers Market Size in USD million (2022-2032)
    • 7.4.2.4. Italy Nebulizers Market Size in USD million (2022-2032)
    • 7.4.2.5. Spain Nebulizers Market Size in USD million (2022-2032)
    • 7.4.2.6. Rest of Europe Nebulizers Market Size in USD million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Nebulizers Market Size in USD million (2022-2032)
    • 7.4.3.2. Japan Nebulizers Market Size in USD million (2022-2032)
    • 7.4.3.3. India Nebulizers Market Size in USD million (2022-2032)
    • 7.4.3.4. Australia Nebulizers Market Size in USD million (2022-2032)
    • 7.4.3.5. South Korea Nebulizers Market Size in USD million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Nebulizers Market Size in USD million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Nebulizers Market Size in USD million (2022-2032)
    • 7.4.4.2. Africa Nebulizers Market Size in USD million (2022-2032)
    • 7.4.4.3. South America Nebulizers Market Size in USD million (2022-2032)

8. Nebulizers Market Company and Product Profiles

• 8.1. Koninklijke Philips N.V.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Omron Healthcare, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Aerogen
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. PARI GmbH
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. GF Health Products, Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Allied Healthcare Products Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. TEKCELEO
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. BMC Medical Co., Ltd.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Medtronic PLC
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Invacare Corporation
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Trudell Medical International
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Nouvag AG
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Timesco Healthcare Ltd.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. LAICA S.p.A.
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Vega Technologies Inc.
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Besco Medical Limited
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. DeVilbiss Healthcare LLC
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Feellife Health Inc.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Convexity Scientific Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Rossmax International Ltd.
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us